The LESS study will evaluate reduced endocrine therapy for HR+/HER2- patients with MammaPrint® Ultra Low tumors to improve quality of life without compromising outcomes Study strengthens Agendia’s growing global footprint in breast cancer to inform Read More
Data show MammaPrint® is the first and most comprehensive FDA-cleared test for early breast cancer resulting in the ability to identify women who may be over- or under-treated if treatment decisions relied on the 21-gene assay Read More
Data demonstrate Research Use Only ImPrint test’s ability to identify patients with high risk early breast cancer who may benefit from PD-1/PD-L1 checkpoint inhibition IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS - June 4, 2022 – Read More
Company to present multiple recent Registry sub-studies driving cancer care innovation at ASCO 2022 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 25, 2022 – Agendia, Inc., a commercial-stage company focused on improving outcomes for Read More
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.